2023 World Conference on Lung Cancer (Posters)-EP08.02. The Value of Combined Immunotherapy in Neoadjuvant Regimen for Patients with Resectable Non-small Cell Lung Cancer

EP08.02. The Value of Combined Immunotherapy in Neoadjuvant Regimen for Patients with Resectable Non-small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

This study aimed to evaluate the prognostic value of combined immunotherapy in the neoadjuvant treatment of patients with resectable non-small cell lung cancer (NSCLC). The researchers compared the outcomes of patients who received neoadjuvant immunochemotherapy or platinum-containing chemotherapy followed by surgery.<br /><br />The results showed that patients who received immunochemotherapy had significantly better recurrence-free survival (RFS) and overall survival (OS) compared to those who received chemotherapy alone. The recurrence rates were also higher in the chemotherapy group, and they were more likely to experience distant or complex recurrence, which was associated with a poorer OS. The combination group had higher rates of major pathological response (MPR) and pathologic complete response (pCR).<br /><br />Furthermore, the study found that patients with MPR had improved RFS and OS, regardless of the treatment received. Even though the MPR was not achieved in all patients, those who received immunochemotherapy still had potentially better RFS and OS. Additionally, patients who did not achieve MPR could benefit from adjuvant therapy.<br /><br />In conclusion, for patients with resectable NSCLC, combined immunotherapy in the neoadjuvant setting resulted in better pathological response, lower recurrence rates, and more limited recurrence compared to chemotherapy alone. Although not all patients achieved MPR, the combined application of immunotherapy extended RFS and OS. This study highlights the potential benefits of incorporating immunotherapy into neoadjuvant treatment regimens for NSCLC patients.

Asset Subtitle

Yu Tian

Meta Tag

Speaker Yu Tian

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

combined immunotherapy

neoadjuvant treatment

resectable non-small cell lung cancer

NSCLC

recurrence-free survival

overall survival

major pathological response

pathologic complete response

adjuvant therapy

treatment regimens